Immunogen, Inc.

ELAHERE

Manufacturer:

Immunogen, Inc.

Elahere HCPCS:

J9063

HCPCS Code Descriptor:

Injection, mirvetuximab soravtansine-gynx, 1 mg

Category:

J Code

Elahere NDCs:

72903-0853-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Elahere:

ELAHERE is a Oncology drug manufactured by Immunogen, Inc. and administered via the Intravenous route of administration. The J Code: J9063 is aligned to the drug ELAHERE.

ELAHERE is a cancer medication under the class of medications known as antineoplastics monoclonal antibody. It works by slowing down and killing the cancer cells. ELAHERE can be used to treat certain types of ovarian cancer, fallopian tube cancer, and peritoneal cancer. This drug is manufactured by Immunogen and is aligned to the HCPCS code J9063.

ACCESS PRICING AND MORE BY REGISTERING

J9063 Added Date:

July 1, 2023

J9063 Effective Date:

July 1, 2023

J9063 Termination Date:

HCPCS Active

Elahere billing and coding information can be found through Immunogen, Inc. at the link below:
Elahere patient assistance information can be found through ELAHERE Support Services at the URL: https://www.elahere.com/support
ELAHERE prescribing information can be found at the link below:
Information regarding ELAHERE’s side effects can be found at MedlinePlus